Search
-
Healthcare vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?
GLP-1s are more than just weight loss drugs. They're a chance to rewrite our evolutionary story, to take control of our biology in a way never before possible.
-
The Rising Tide of Private Labels: How name brands can stay afloat
By embracing innovation, building strong brand equity, enhancing the customer experience, and adopting strategic partnerships and omnichannel strategies, name brands can thrive in the face of competition.
-
The Heart Truth: Understanding What We Don’t Know About Cardiac Health
New Ipsos survey conducted across six countries reveals that despite 84% claiming to be sufficiently informed on the cardiac health, only less than a half are.
-
U.S. Biosimilars: Greater Access and New Commercial Models
Read more about the primary considerations that manufacturers – of both biosimilars and originator products – must factor into strategic plans going forward.
-
What the Future: Food
Revisit our on-demand webinar for exclusive polling data on nutrition, sustainability, diets and consumer spending, plus highlights and excerpts from interviews with industry experts.
-
How GLP-1s create opportunities for brands and retailers to address new self-care needs
CPG companies and retailers can act as trusted advisors and provide valuable advice and information, such as diet plans, exercise regimens, and ways to manage medication side effects. Here’s where to start.
-
Golden Years, Golden Opportunities
Read more about what an aging consumer base means for businesses, how to tap into the wealth held by this cohort, and who among older adults is spending – and on what.
-
Reshaping Society: Insights to Activate
GLP-1s have the potential to make a massive impact on the global economy. Stakeholders in various industries must adapt, and proactively, to stay ahead of the curve. Here’s how.
-
How ads went for gold at the 2024 Summer Games
How effective were this year’s Summer Games ads? Using Creative|Spark AI, Ipsos’ AI-powered ad assessment tool, we tested 31 ads across multiple different categories. Here’s what we learned.